



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ceftriaxone-¹³C₂,d₃ triethylammonium salt

Cat. No.:	HY-B0712S1
Molecular Formula:	C ₂₂ ¹³ C ₂ H ₃₀ D ₃ N ₉ O ₇ S ₃
Molecular Weight:	660.77
Target:	Antibiotic; Aurora Kinase; GSK-3; Bacterial; Isotope-Labeled Compounds
Pathway:	Anti-infection; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ceftriaxone- ¹³ C ₂ ,d ₃ triethylammonium salt is ¹³ C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC ₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis ^{[1][2][3][4][5][6][7]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . Ceftriaxone (100 μM, 24 h) protects MPP ⁺ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [4]. Ceftriaxone (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Ceftriaxone (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury ^[6] . Ceftriaxone (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylene tetrazol (PTZ) and PTZ-related oxidative damage in rats ^[7] . Ceftriaxone (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in Streptozocin (HY-13753)-induced diabetic rat models ^[8] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. *Drug Intell Clin Pharm.* 1985 Dec;19(12):900-6.
- [2]. Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. *RSC Adv.* 2023 Apr 11;13(17):11278-11290.
- [3]. Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP(+) via Suppression of NF-κB/JNK/c-Jun Signaling. *Mol Neurobiol.* 2015 Aug;52(1):78-92.
- [4]. Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. *Carcinogenesis.* 2012 Dec;33(12):2548-57.

-
- [5]. Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. *Life Sci.* 2020 Oct 1;258:118119.
- [6]. Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. *Int J Neurosci.* 2016;126(1):70-5.
- [7]. Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. *Neurosci Lett.* 2011 Mar 10;491(1):23-5.
- [8]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA